Hideho Okada, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hideho Okada, MD, PhD

Professor of Neurological Surgery, Surgery and Immunology, UCSF

okadah@neurosurg.ucsf.edu

Box 0520, UCSF
San Francisco, CA 94158

View on UCSF Profiles

Research Summary

As a physician scientist, I have been dedicated to brain tumor immunology and development of effective immunotherapy for brain tumors for over 20 years. My team was one of very first to discover cytotoxic T lymphocyte (CTL) epitopes in glioma-associated and glioma-specific neoantigens, and found critical roles for the integrin receptor known as very late activation antigen (VLA)-4 in facilitating entry of CTLs to the brain tumor site. I have translated these discoveries into novel vaccine and immune-gene therapy clinical studies in both adult and pediatric brain tumor patients. I am a member in the American Society for Clinical Investigation (2010-present), an honored society for physicians who promote laboratory science to the clinic. My current national and international leadership roles include: chair of the immunotherapy subgroup at the NCI-sponsored Adult Brain Tumor Consortium; a Steering Committee member of the Cancer Immunology Working Group in the American Association for Cancer Research (AACR); a co-chair for Education Day at 2015 the Society for Neuro-Oncology annual meeting; and an Organizing Committee member for the 2015 Annual Meeting of the AACR.

Education

Nagoya University School of Medicine-Japan, M.D., 1991, Medicine
Nagoya University School of Medicine-Japan, Ph.D., 1996, Medicine
Handa Municipal Hospital-Japan, Internship, Residency, 1991-1992
Nagoya University School of Medicine-Japan, Residency, 1992-1996, Neurosurgery


Professional Experience

  • 1998-2001
    Research Assistant Professor, Department of Neurosurgery, UPSOM 
  • 2001-2006
    Assistant Professor, Department of Neurosurgery and Surgery, UPSOM
  • 2004-present
    Co-Program Leader, Brain Tumor Program, University of Pittsburgh Cancer Institute
  • 2007-2012
    Associate Professor, Department of Neurosurgery and Surgery, UPSOM
  • 2012-present
    Professor, Department of Neurosurgery, Surgery and Immunology UPSOM

Honors & Awards

  • 1996
    Uehara Memorial Foundation Postdoctoral Scholarship
  • 1998
    First Place, Award for Scientific Excellence and Potential, 10th Annual University of Pittsburgh, Cancer Institute Scientific Retreat
  • 2001
    Doris Duke Charitable Foundation’s Clinical Scientist Development Award
  • 2003
    James S. McDonnell Foundation 21st Century Science Initiative Research Award: Brain Cancer Research
  • 2007
    Excellence in Translational Medicine Award 2006-07 from Journal of Translational Medicine
  • 2008
    University of Pittsburgh Innovator Award
  • 2010
    Team Science Recognition Award by Society for Immunotherapy of Cancer
  • 2011
    Faculty Honoree in the Annual Convocation of University of Pittsburgh

Selected Publications

  1. Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging therapy in the management of patients with diffuse low grade glioma. J Neurooncol. 2015 Dec; 125(3):631-5.
    View on PubMed
  2. Dunn GP, Okada H. Principles of immunology and its nuances in the central nervous system. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii3-vii8.
    View on PubMed
  3. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-42.
    View on PubMed
  4. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46.
    View on PubMed
  5. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22.
    View on PubMed
  6. Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H. Transgene-derived overexpression of miR-17-92 in CD8(+) T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun. 2015 Mar 13; 458(3):549-54.
    View on PubMed
  7. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508.
    View on PubMed
  8. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014; 2(1):46.
    View on PubMed
  9. Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. Clin Cancer Res. 2015 Jan 15; 21(2):286-94.
    View on PubMed
  10. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, Watkins SC, Sarkar SN, Okada H. STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment. Cancer Immunol Res. 2014 Dec; 2(12):1199-208.
    View on PubMed
  11. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 1; 32(19):2050-8.
    View on PubMed
  12. Kosaka A, Ohkuri T, Okada H. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother. 2014 Aug; 63(8):847-57.
    View on PubMed
  13. Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, Okada H. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013; 1:21.
    View on PubMed
  14. Ahn BJ, Pollack IF, Okada H. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel). 2013; 5(4):1379-412.
    View on PubMed
  15. Pollack IF, Jakacki RI, Butterfield LH, Okada H. Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother. 2013 Oct; 13(10):1089-98.
    View on PubMed
  16. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-a. Cancer Res. 2013 Nov 1; 73(21):6413-23.
    View on PubMed
  17. Pollack IF, Jakacki RI, Butterfield LH, Okada H. Peptide vaccine therapy for childhood gliomas. Neurosurgery. 2013 Aug; 60 Suppl 1:113-9.
    View on PubMed
  18. Zhong J, Sakaki M, Okada H, Ahrens ET. In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging. PLoS One. 2013; 8(5):e59479.
    View on PubMed
  19. Okada H, Scheurer ME, Sarkar SN, Bondy ML. Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci. 2013 May; 1284:17-23.
    View on PubMed
  20. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol. 2013 Jul; 15(7):891-903.
    View on PubMed

Go to UCSF Profiles, powered by CTSI